Sinogliatin

Drug Profile

Sinogliatin

Alternative Names: HMS-5552; RO-5305552

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Hua Medicine
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucokinase stimulants; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 18 Jul 2017 Phase-III clinical trials in Type-2 diabetes mellitus in China (PO) (NCT03173391)
  • 06 Jun 2017 Hua Medicine plans a phase III trial for Type-2 diabetes mellitus (PO) (NCT03173391)
  • 09 May 2017 Hua Medicine plans a phase III trial for Type-2 diabetes mellitus (Adjunctive therapy) (PO) (NCT03141073)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top